Pharma Manufacturing Expansion MA Impacts Charles City Site
- Cambrex has invested $50 million to boost its large-scale API manufacturing capabilities.
- The upgraded facility is now equipped to handle large-scale production of peptides utilizing standard batch reactors.This capability is crucial as peptide-based therapeutics continue to gain prominence in the...
- Cambrex is a leading global CDMO providing services across the entire drug lifecycle.
Cambrex Expands API Manufacturing Capacity with $50 Million Investment
Table of Contents
published August 30, 2025 at 19:05:16
Expansion Details and Increased Capacity
Cambrex has invested $50 million to boost its large-scale API manufacturing capabilities. The expansion has resulted in approximately 25,000 gallons of reactor capacity, positioning the facility as one of the most advanced API plants in the United States. This considerable increase in capacity allows Cambrex to meet the escalating demands of the pharmaceutical market.
The upgraded facility is now equipped to handle large-scale production of peptides utilizing standard batch reactors.This capability is crucial as peptide-based therapeutics continue to gain prominence in the treatment of various diseases. peptides are increasingly crucial in drug development due to their high potency and specificity.
Cambrex and the Growing Peptide Market
Cambrex is a leading global CDMO providing services across the entire drug lifecycle. The company specializes in small molecule API development and manufacturing, as well as offering capabilities in areas like controlled substances, highly potent APIs, and continuous flow chemistry. Cambrex’s website provides further details on their services and capabilities.
The demand for peptide APIs is experiencing notable growth, driven by advancements in biotechnology and the increasing number of peptide-based drugs in development. According to a report by Grand View Research, the global peptide market was valued at USD 10.87 billion in 2023 and is projected to reach USD 26.48 billion by 2030, growing at a CAGR of 13.8% from 2024 to 2030. This expansion by Cambrex directly addresses this growing market need.
Implications for the Pharmaceutical Industry
The increased API manufacturing capacity at Cambrex has several implications for the pharmaceutical industry. Firstly, it provides pharmaceutical companies with a reliable partner for large-scale peptide production, reducing supply chain risks. Secondly, it can potentially accelerate the development and commercialization of new peptide-based therapies.the advanced technology incorporated into the facility may lead to more efficient and cost-effective manufacturing processes.
The availability of increased API capacity is particularly important in the context of ongoing global health challenges and the need for rapid drug development and manufacturing. This investment by Cambrex contributes to a more resilient and responsive pharmaceutical supply chain.